PharmEasy, through Docon Technologies, sold 9.9% of its Thyrocare stake to repay ₹1,050 crore in outstanding debt. This marks the end of a contentious debt refinancing saga and keeps PharmEasy's controlling stake in Thyrocare intact. The company now claims to be debt-free, a significant turnaround from its valuation struggles last year.
How We Got Here
API Holdings proposed raising ₹1,700 Cr last year through NCDs to refinance existing debentures worth ₹1,545.38 Cr. At the time, Docon Technologies had pledged 71.06% of its Thyrocare holding as security, which was later adjusted to 60.93% after a bonus issue.
The Numbers
- The repayment of ₹1,050 Cr in secured, unlisted, and redeemable NCDs occurred on August 14.
- Docon Technologies sold 1.58 Mn Thyrocare shares via open market trades, raising part of the funds for repayment.
- Following the sale, Docon Technologies retains a 51.02% controlling stake in Thyrocare.
- The previous pledge over Docon's Thyrocare shares, held by Catalyst Trusteeship, has been fully released.
- Thyrocare reported a 34.1% YoY jump in net profit to ₹52.19 Cr in the latest quarter, with operating revenue growing 24.3% YoY.
What Happens Next
🇮🇳 Why This Matters for India
For healthtech founders and investors in Bangalore and Hyderabad, PharmEasy's move offers a template for navigating complex debt situations while retaining core asset control.
The Take
PharmEasy might be "debt-free" on paper, but the real cost was shedding a significant chunk of its most profitable asset, Thyrocare, to achieve it. The narrative of "retaining control" at 51% misses the point: they've just sold off future upside from a strong performer to clear immediate liabilities, which is a trade-off, not a pure win.
Source:
Inc42 ↗